📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Valaciclovir for Epstein-Barr Virus Suppression in Moderate-to-Severe COPD: A Randomized Double-Blind Placebo-Controlled Trial. (2023)

First Author: Linden DA

Attributed to: The role of Cathepsin S in PAR-1 mediated lung inflammation - a new paradigm for neutrophilic inflammation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.chest.2023.03.040

PubMed Identifier: 37011709

Publication URI: http://europepmc.org/abstract/MED/37011709

Type: Journal Article/Review

Volume: 164

Parent Publication: Chest

Issue: 3

ISSN: 0012-3692